Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

  • End date
    Dec 31, 2027
  • participants needed
  • sponsor
    Washington University School of Medicine
Updated on 14 July 2022


The investigators hypothesize that flotetuzumab for relapsed AML following allo-HCT will be safe, tolerable and may facilitate preferential immune effector cell retargeting of leukemic cells resulting in improved patient outcomes. Furthermore, administration of a donor lymphocyte infusion (DLI) (if available) in combination with flotetuzumab will be safe, tolerable and may provide additional therapeutic efficacy.

Condition Relapsed Acute Myeloid Leukemia
Treatment MGD006, Donor Lymphocyte Infusion, Flotetuzumab
Clinical Study IdentifierNCT04582864
SponsorWashington University School of Medicine
Last Modified on14 July 2022


Yes No Not Sure

Inclusion Criteria

Histologically or cytologically confirmed relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), including any AML subtype, except acute promyelocytic leukemia (APL), and including AML that has evolved from a previous MDS or MPN
Patients must have peripheral blast count ≤ 20,000/mm3. Use of hydroxyurea to control blast count is permitted
Patients must be status post allo-HCT (including: matched related, matched unrelated, haploidentical, mismatched unrelated; and cord blood HCT)
Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2
Adequate organ function, defined as
Hepatic transaminase (both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels ≤2.5 times the institutional upper limit of normal (ULN)
Total bilirubin level ≤1.5 times the ULN (unless the patient has a history of Gilbert's Syndrome, in which case, total bilirubin must be ≤2.5 times the ULN)
Creatinine clearance of ≥50 ml/min
Adequate organ reserve including cardiovascular (ejection fraction within institutional normal limits), pulmonary (baseline pulmonary function test [PFT]: carbon monoxide diffusion capacity in the lung [DLCO] > 50%, forced expiratory volume in 1 second [FEV1] > 70%), renal, and hepatic functioning sufficient, in the judgment of the Investigator, to undergo therapy
Normal thyroid function or stable thyroid tests on supplementation, except euthyroid sick syndrome
Recovery from toxicities of clinical consequence attributed to previous chemotherapy
Female patients of childbearing potential must test negative for pregnancy at enrollment and during the study. Sexually active women of child-bearing potential, unless surgically sterile, must be willing to use a highly effective method of birth control defined as those which result in a low failure rate (i.e., less than 1% per year) such as implants, injectables, combined oral contraceptives, intra-uterine devices (IUDs) or vasectomized partner. Male patients with partners of childbearing potential must be either vasectomized or agree to use a condom in addition to having their partners use another method of contraception resulting in a highly effective method of birth control defined as those which result in a low failure rate (i.e., less than 1% per year) such as implants, injectables, combined oral contraceptives, or IUDs. Patients should not have sexual intercourse with females who are either pregnant or lactating without a condom. Contraception should be employed from the time of consent through 12 weeks after MGD006 administration. Patients should also abstain from sperm/egg donation during the course of the study
to CTCAE v4.0 Grade ≤ 1 (i.e., certain toxicities such as alopecia will not be
considered in this category)
Able to have non-steroidal immunosuppression discontinued, including
mycophenolate (MMF)
Able to have corticosteroids weaned to ≤0.5mg/kg prednisone/day (or equivalent)
calcineurin inhibitors (tacrolimus, cyclosporine)
calcineurin inhibitors must be able to be discontinued at least 14 days
prior to enrolling on study
JAK inhibitors (ruxolitinib)
MTOR inhibitors (sirolimus)
At least 18 years of age
Ability to understand and willingness to sign an IRB approved written informed consent document

Exclusion Criteria

Active GVHD requiring systemic immunosuppresion with more than 0.5 mg/day prednisone
Currently receiving any other investigational agents
Any active untreated autoimmune disorders (with the exception of vitiligo, resolved childhood atopic dermatitis, prior Grave's disease now euthyroid clinically and with stable supplementation)
Second primary malignancy that requires active therapy (adjuvant hormonal therapy is allowed)
Antitumor therapy (chemotherapy, radiotherapy, antibody therapy, molecular- targeted therapy, retinoid therapy, or investigational agent) within 14 days or 5 half-lives of Cycle 1 Day 1, whichever is longer
At the time of study entry, steroids >0.5mg/kg of prednisone or equivalent (except steroid inhaler, nasal spray or ophthalmic solution which are allowed)
Use of immunosuppressant medications (other than steroids as noted) in the 2 weeks prior to study drug administration (Cycle 1 Day 1)
Isolated extramedullary relapse (i.e., no evidence of bone marrow involvement)
Known central nervous system (CNS) leukemia. Patients with suspected CNS leukemia must be evaluated by lumbar puncture and be free of CNS disease prior to study entry. Previously treated CNS leukemia is allowed provided adequate treatment has been provided and the patient is free of CNS disease
Any medical or psychiatric condition limiting full compliance or increasing the safety risk, at the discretion of the PI, such as
active uncontrolled infection (including, but not limited to viral, bacterial, fungal, or mycobacterial infection)
known human immunodeficiency virus infection
known, active, or chronic hepatitis B or C infection (appropriately treated HBV/HCV infections with documented clearance of viral titer are allowed)
Grade 3 or 4 bleeding
significant pulmonary compromise including the requirement for supplemental oxygen, history of non-infectious pneumonitis (including radiation pneumonitis), pulmonary fibrosis, or severe chronic obstructive pulmonary disease (COPD)
uncontrolled (persistent) hypertension (systolic pressure > 180 mm Hg or diastolic pressure > 100 mm Hg
clinically significant arrhythmia, clinically significant baseline QTcF >480 msec
unstable angina
recent myocardial infarction within 6 months prior to study drug administration (Cycle 1 Day 1)
clinically significant heart disease, such as, congestive heart failure, history of pericarditis, myocarditis
history of stroke or transient ischemic event within 3 months prior to study drug administration (Cycle 1 Day 1)
untreated pulmonary embolism, or non-catheter-related deep-vein thrombosis in the 3 months prior to study drug administration (Cycle 1 Day 1)
pregnancy, or breast feeding
major surgery or trauma within 4 weeks before enrollment
Dementia or altered mental status that would preclude sufficient understanding to provide informed consent
Known hypersensitivity to murine, yeast, or recombinant proteins; polysorbate 80
recombinant human serum albumin; benzyl alcohol; or any excipient contained in
the MGD006 drug formulation
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note